Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 18:15:17588359231161409.
doi: 10.1177/17588359231161409. eCollection 2023.

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer

Natalie I Vokes  1   2 , Kelsey Pan  3 , Xiuning Le  4
Affiliations
Review

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer

Natalie I Vokes et al. Ther Adv Med Oncol. .

Abstract

For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majority of patients with lung adenocarcinoma will be eligible for a targeted therapy during their treatment course. With these emerging therapeutic options, it is important to understand the existing data on immune checkpoint inhibitors (ICIs), along with their efficacy and safety for each oncogene-driven lung cancer, to best guide the selection and sequencing of various therapeutic options. This article reviews the clinical data on ICIs for each of the driver oncogene defined lung cancer subtypes, including efficacy, both for ICI as monotherapy or in combination with chemotherapy or radiation; toxicities from ICI/targeted therapy in combination or in sequence; and potential strategies to enhance ICI efficacy in oncogene-driven non-small-cell lung cancers.

Keywords: immunotherapy; lung cancer; oncogene; precision oncology.

PubMed Disclaimer

Conflict of interest statement

XL receives consulting/advisory fees from AstraZeneca, EMD Serono (Merck KGaA), Spectrum Pharmaceutics, Novartis, Eli Lilly, Boehringer Ingelheim, Hengrui Therapeutics, Janssen, Blueprint Medicines, Sensei Biotherapeutics, Daiichi Sankyo, Bicara, Regeneron, ArriVent, Abion, Pinetree therapeutics, and Abbvie. XL receives research funding to the institution from Eli Lilly, EMD Serono, Regeneron, Janssen, Boehringer Ingelheim, ArriVent, and Teligene. NIV receives consulting/advisory feeds from Regeneron, Sanofi, Eli Lilly, OncoCyte, and research funding from Mirati.

Figures

Figure 1.
Figure 1.
ICI monotherapy ORR and mPFS in NSCLC by driver oncogenes. *Bars reflect overall ORR (blue) and mPFS (green) demonstrated in retrospective IMMUNOTARGET study. **Vertical orange lines depict ORRs shown in other individual ICI monotherapy trials. ICIs, immune checkpoint inhibitors; mPFS, median progression-free survival; NSCLC, non-small-cell lung cancer; ORR, overall response rate.
See this image and copyright information in PMC

References

    1. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 2004; 101: 13306–13311. - PMC - PubMed
    1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–2139. - PubMed
    1. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500. - PubMed
    1. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540–1550. - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 2016; 375: 1823–1833. - PubMed

LinkOut - more resources